Business
Cellectar Biosciences Announces CLR 131 Achieves Primary Efficacy Endpoints from Its Phase 2 CLOVER-1 Study in Relapsed/Refractory B-cell Lymphomas and Completion of the Phase 1 Relapsed/Refractory Multiple Myeloma Dose Escalation Study
42.8% ORR in multiple myeloma at the 75mCi total body dose 42.0% ORR and 11% CRR in all non-Hodgkin’s lymphoma (NHL) patients 100% ORR seen in
About this update from Cellectar Biosciences, Inc.
[{"type":"text","content":"42.8% ORR in multiple myeloma at the 75mCi total body dose\n 42.0% ORR and 11% CRR in all non-Hodgkin’s lymphoma (NHL) patients 100% ORR seen in Lymphoplasmacytic Lymphoma/Waldenstrom’s Macroglobulinemia (LPL/WM) patients 76.7% of the multiple myeloma patients across all doses tested experienced tumor reduction with a strong dose response FLORHAM PARK, N.J., Feb. 19, 2020 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announced positive data from its Phase 2 CLOVER-1 study in patients with relapsed/refractory B-cell lymphomas. Additionally, the company announced the successful completion of its Phase 1 dose escalation study. Data from the studies demonstrated activity in all indications tested: multiple myeloma (MM), diffuse large B-cell lymphoma (DLBCL), chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), marginal zone lymphoma (MZL), mantle cell lymphoma (MCL), and lymphoplasmacytic lymphoma/Waldenstrom’s macroglobulinemia (LPL/WM). CLR 131 achieved notable response rates in patients with multiple myeloma - 34.5% overall response rate (ORR) over all therapeutic doses (n=33), and non-Hodgkin’s lymphoma (NHL) - 42% ORR over all doses (n=20) while maintaining a well-tolerated safety profile across all patients. Based upon these positive results and corroborating data showing the potential to further improve upon current overall response rates and durability of those responses, the study has been expanded to test a two-cycle dosing optimization regimen of CLR 131. Patients in the studies were heavily pre-treated, with multiple myeloma patients having a median of five prior treatment regimens (range: 3 to 17), which included immunomodulatory drugs, proteasome inhibitors and CD38 antibodies for the majority of patients. Additionally, a majority of the patients (51%) were quad refractory or greater and 44% of all treated multiple myeloma patients were triple class refractory. NHL patients in the study were also heavily pre-treated, having had a median of 3 prior lines of treatment (range, 1 to 9) with the majority of patients being refractory to rituximab and/or ibrutinib. In both groups, the patients had a median age of 70 with a range of 51 to 86. Relapsed...